ClinicalTrials.gg
RecruitingNCT07236463IRON-ICUpdated Jun 5, 2026

Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury

A Phase 1/2 interventional study of Continuous veino-veinous dialysis with iron-chelator supplemented dialysate in Acute Kidney Injury and Sepsis, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 154 studies in Acute Kidney Injury with a site in France — 31 open to participants now, 35 under way, 4 of them phase 3. Acute Kidney Injury · France.

Planned enrollment
73rd of 78
14 · median 150
Started
2026
with 3 others
Phase 1/2
Only one
of the 154
Primary completion
2027-06
later than 22 of 34 live
Registered
150th of 154
by date
Lead sponsor
9 of 154
Centre Hospitalier Universitaire de Nīmes

Among the 154 studies in Acute Kidney Injury with a site in France, this one is the 73rd largest by planned enrollment of the 78 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 22 of the 34 other live ones, and was the 150th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

31 of the 154 studies in Acute Kidney Injury with a site in France are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Acute Kidney Injury with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if adding the iron-binding drug MEX-CD1 to dialysis fluid can help remove excess iron in adults with sepsis-associated acute kidney injury (AKI) requiring dialysis who are in the intensive care unit (ICU). The main questions it aims to answer are:

Does adding MEX-CD1 to the dialysis fluid increase the amount of iron removed during dialysis? Is using MEX-CD1 in dialysis fluid safe for patients?

Participants will:

Be adults in the ICU with sepsis-associated AKI who need continuous dialysis (renal replacement therapy) Receive two 24-hour dialysis sessions: one with standard dialysis fluid and one with dialysis fluid containing MEX-CD1 Serve as their own control, meaning they will receive both treatments

Researchers will measure:

The amount of iron removed in the dialysis waste fluid (primary outcome) Blood levels of iron Changes in other trace elements Markers of inflammation and oxidative stress Safety outcomes up to 28 days after treatment This is a pilot study being done at a single hospital in France.

Read the detailed description

Sepsis-associated acute kidney injury (AKI) is a common and serious complication in critically ill patients admitted to intensive care units (ICUs). It is associated with high rates of death and long-term health problems. Currently, there is no specific treatment to address the underlying causes of this condition beyond supportive measures such as dialysis to replace kidney function.

A growing body of research suggests that excess circulating labile (easily reactive) iron plays an important role in the development of organ injury during sepsis. Labile iron can promote oxidative stress, mitochondrial damage, and cell death through a process called ferroptosis. Reducing the amount of labile iron in the bloodstream may help limit these harmful effects.

This study is designed to evaluate a new approach to lowering labile iron levels during continuous renal replacement therapy (CRRT) in patients with sepsis-associated AKI. The investigational strategy uses an iron-binding compound (iron chelator) called MEX-CD1 added to the dialysis fluid (dialysate) during continuous veno-venous hemodialysis (CVVHD). By binding iron in the dialysis circuit, the chelator aims to enhance the removal of labile iron from the patient's blood without requiring systemic administration of the chelating agent.

This is a single-centre, randomised, open-label, two-period crossover phase I-II pilot study conducted in the ICU of Nîmes University Hospital in France. Each participant will undergo two consecutive 24-hour sessions of CVVHD, one using standard dialysate and one using dialysate supplemented with MEX-CD1 at a concentration of 50 mg/L. The order of the sessions will be randomised so that each participant serves as their own control, helping to reduce variability due to individual differences in illness severity or metabolism.

The primary objective of the study is to assess the performance of iron removal by measuring the concentration of iron in the dialysis effluent. Secondary objectives include evaluating plasma iron clearance, monitoring for loss of other trace elements, and assessing biomarkers related to oxidative stress and inflammation. Safety outcomes will also be closely monitored during the dialysis sessions and for 28 days afterward, including any adverse events related to the use of MEX-CD1 in the dialysate.

This pilot study will generate preliminary data on the feasibility, safety, and potential effectiveness of this novel dialysis-based iron removal strategy. If successful, it may support the development of larger trials aimed at improving outcomes for critically ill patients with sepsis-associated AKI.

03

Conditions studied

  • Acute Kidney Injury
  • Sepsis

Keywords

  • Acute Kidney Injury
  • Sepsis
  • Continuous Renal Replacement Therapy
  • Iron Chelating Agents
  • Intensive Care Unit
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Adult patients (≥18 years) admitted to ICU with sepsis-associated AKI requiring CRRT
  • Sepsis defined according to SEPSIS-3 criteria (suspected/documented infection with organ dysfunction indicated by ≥2-point increase in SOFA [Sequential Organ Failure Assessment] score)
  • AKI Stage 3 per KDIGO (Kidney Disease: Improving Global Outcomes) criteria: acute rise in serum creatinine ≥3 times baseline or serum creatinine ≥4 mg/dL or urine output \<0.3 mL/kg/h for ≥24 hours or anuria (urine output \<100ml) for ≥12 hours
  • Indications for CRRT: hyperkalemia (>6 mmol/L) or refractory metabolic acidosis (pH \< 7.20) or acute pulmonary edema unresponsive to medical management or urine output \<0.3 ml/kg/hour or anuria (urine output \<100ml) persistent for 48 hours and refractory to medical treatment
  • obtained from patient or legal representative
  • Affiliated with or beneficiary of a health insurance plan

Exclusion Criteria:

  • Known shellfish allergy
  • Moribund status with too low to benefit
  • Concurrent participation in another interventional study
  • Exclusion period defined by another study
  • Under legal protection (guardianship or curatorship)
  • Inability to obtain informed consent from patient or representative
  • Pregnant, parturient, or breastfeeding women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
14 participants (estimated)

Study arms

  • Other
    Sequence A: MEX-CD1-supplemented dialysate first, then standard dialysate

    Participants will receive two consecutive 24-hour CVVHD sessions using: * Standard Dialysate: Commercially available CiCa™ dialysate (Fresenius Medical Care, Germany) * MEX-CD1 Dialysate: CiCa™ dialysate supplemented with MEX-CD1 at 50 mg/L (28). MEX-CD1 remains confined to the dialysate, separated from the patient's circulation by the dialysis membrane because of its molecular weight

    Combination Product: Continuous veino-veinous dialysis with iron-chelator supplemented dialysate

  • Other
    Sequence B: Standard dialysate first, then MEX-CD1-supplemented dialysate

    Participants will receive two consecutive 24-hour CVVHD sessions using: * Standard Dialysate: Commercially available CiCa™ dialysate (Fresenius Medical Care, Germany) * MEX-CD1 Dialysate: CiCa™ dialysate supplemented with MEX-CD1 at 50 mg/L (28). MEX-CD1 remains confined to the dialysate, separated from the patient's circulation by the dialysis membrane because of its molecular weight

    Combination Product: Continuous veino-veinous dialysis with iron-chelator supplemented dialysate

Interventions

  • Combination productContinuous veino-veinous dialysis with iron-chelator supplemented dialysate

    Participants will receive two consecutive 24-hour CVVHD sessions using: * Standard Dialysate: Commercially available CiCa™ dialysate (Fresenius Medical Care, Germany) * MEX-CD1 Dialysate: CiCa™ dialysate supplemented with MEX-CD1 at 50 mg/L (28). MEX-CD1 remains confined to the dialysate, separated from the patient's circulation by the dialysis membrane because of its molecular weight Both sessions will use identical RRT parameters, no dose escalation is planned: * Continuous veno-venous hemodialysis (CVVHD) modality * Multifiltrate™ dialyzer (Fresenius Medical Care, Germany) with regional citrate anticoagulation * Dialysis dose of 20-25 mL/kg/h (approx. 1600 mL/h dialysate flow) * Blood flow 80 mL/min * Ultrasound-guided placement of a 15 cm 16 F double-lumen catheter in the right internal jugular vein * The circuit and the dialysis filter will be changed after each 24 hours CVVHD session

06

What researchers measure

Primary outcomes

  1. Free iron concentrations in the dialysis effluent

    The primary outcome is defined as the comparison of free iron concentrations in the effluent collected during 24-hour dialysis sessions performed under two conditions: using standard dialysate and using dialysate supplemented with the iron chelator MEX-CD1.

    Time frame: 48 hours (2 consecutive sessions of 24 hours CVVHD)

Secondary outcomes

  1. 24-hour serum iron clearance

    24-hour serum iron clearance with iron chelation by addition of MEX-CD1 to the dialysate.

    Time frame: 48 hours

  2. ratio iron clearance/creatinine clearance

    Compare the ratio of 24-hour plasma iron clearance to creatinine clearance between standard dialysate and MEX-CD1-supplemented dialysate.

    Time frame: 48 hours

  3. Plasma malondialdehyde concentration

    The impact of iron chelation, achieved by adding MEX-CD1 to the dialysate, will be assessed on oxidative stress biomarkers by measuring plasma malondialdehyde concentrations every 8 hours for 48 hours.

    Time frame: From enrollment until the end of the intervention at 48 hours.

  4. Plasma Thiobarbituric Acid Reactive Substances (TBARS)

    The impact of iron chelation, achieved by adding MEX-CD1 to the dialysate, will be assessed on oxidative stress biomarkers by measuring Plasma Thiobarbituric Acid Reactive Substances (TBARS) concentrations every 8 hours for 48 hours.

    Time frame: From enrollment until the end of the intervention at 48 hours.

  5. Plasma protein thiols

    The impact of iron chelation, achieved by adding MEX-CD1 to the dialysate, will be assessed on oxidative stress biomarkers by measuring plasma protein thiol concentrations every 8 hours for 48 hours.

    Time frame: From enrollment until the end of the intervention at 48 hours.

  6. Plasma Glutathione Peroxidase (GPx) concentration

    The impact of iron chelation, achieved by adding MEX-CD1 to the dialysate, will be assessed on oxidative stress biomarkers by measuring plasma Glutathione Peroxidase (GPx) concentrations every 8 hours for 48 hours.

    Time frame: From enrollment until the end of the intervention at 48 hours.

  7. Plasma C-reactive protein levels

    The impact of iron chelation, achieved by adding MEX-CD1 to the dialysate, will be assessed on inflammatory biomarkers by measuring plasma C-reactive protein levels every 8 hours for 48 hours.

    Time frame: From enrollment until the end of the intervention at 48 hours.

  8. Plasma procalcitonin levels

    The impact of iron chelation, achieved by adding MEX-CD1 to the dialysate, will be assessed on inflammatory biomarkers by measuring plasma procalcitonin levels every 8 hours for 48 hours.

    Time frame: From enrollment until the end of the intervention at 48 hours.

Other outcomes

  1. Number of participants with potentially treatment-related adverse events, as assessed by CTCAE v6.0, during the intervention.

    Safety will be assessed by the incidence of potentially treatment-related adverse events during the first 48 hours of renal replacement therapy with standard dialysate or dialysate supplemented with MEX-CD1, including hypotension, cutaneous erythema, and other non-prespecified events, classified according to CTCAE v6.0.

    Time frame: From enrollment until the end of the intervention at 48 hours.

  2. Number of participants with potentially treatment-related adverse events, as assessed by CTCAE v6.0, after the intervention.

    Long-term safety will be assessed by the incidence of potentially treatment-related adverse events occurring after the first 48 hours of the intervention (renal replacement therapy with standard dialysate or dialysate supplemented with MEX-CD1) and up to day 28, including anemia, low serum iron levels, and other non-prespecified events, classified according to CTCAE v6.0.

    Time frame: From the end of the intervention at Hour 48 until Day 28 or ICU discharge, whichever occurs first

  3. Serum iron levels

    the investigators will evaluate the impact of iron chelation (by adding MEX-CD1 to the dialysate) on iron balance up to Day 28. Serum iron will be measured at Day 0, Day 1, Day 2, Day 7, and Day 28."

    Time frame: 28 Days

  4. Serum transferrin levels

    the investigators will evaluate the impact of iron chelation (by adding MEX-CD1 to the dialysate) on iron metabolism markers up to Day 28. Serum transferrin levels will be measured at Day 0, Day 1, Day 2, Day 7, and Day 28.

    Time frame: 28 days

  5. Serum ferritin levels

    the investigators will evaluate the impact of iron chelation (by adding MEX-CD1 to the dialysate) on iron metabolism markers up to Day 28. Serum ferritin levels will be measured at Day 0, Day 1, Day 2, Day 7, and Day 28.

    Time frame: 28 days

  6. Serum soluble transferrin receptor (sTfR) levels

    the investigators will evaluate the impact of iron chelation (by adding MEX-CD1 to the dialysate) on iron metabolism markers up to Day 28. Serum soluble transferrin receptor (sTfR) levels will be measured at Day 0, Day 1, Day 2, Day 7, and Day 28.

    Time frame: 28 days

  7. Serum hepcidin levels

    the investigators will evaluate the impact of iron chelation (by adding MEX-CD1 to the dialysate) on iron metabolism markers up to Day 28. Serum hepcidin levels will be measured at Day 0, Day 1, Day 2, Day 7, and Day 28.

    Time frame: 28 days

  8. 24-hour copper clearance

    Measurement of 24-hour copper clearance after a dialysis session with MEX-CD1 added to the dialysate or with standard dialysate. Copper clearance will be calculated as: (effluent copper concentration × effluent volume over 24 hours) / serum copper concentration.

    Time frame: 48 hours

  9. 24-hour selenium clearance

    Measurement of 24-hour selenium clearance after a dialysis session with MEX-CD1 added to the dialysate or with standard dialysate. Selenium clearance will be calculated as: (effluent selenium concentration × effluent volume over 24 hours) / serum selenium concentration.

    Time frame: 48 hours

  10. 24-hour plasma zinc clearance

    Measurement of 24-hour zinc clearance after a dialysis session with MEX-CD1 added to the dialysate or with standard dialysate. Zinc clearance will be calculated as: (effluent zinc concentration × effluent volume over 24 hours) / serum zinc concentration.

    Time frame: 48 hours

  11. 24-hour aluminium clearance

    Measurement of 24-hour aluminium clearance after a dialysis session with MEX-CD1 added to the dialysate or with standard dialysate. Aluminium clearance will be calculated as: (effluent aluminium concentration × effluent volume over 24 hours) / serum aluminium concentration.

    Time frame: 48 hours

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Grange C, Lux F, Brichart T, David L, Couturier A, Leaf DE, Allaouchiche B, Tillement O. Iron as an emerging therapeutic target in critically ill patients. Crit Care. 2023 Dec 4;27(1):475. doi: 10.1186/s13054-023-04759-1. PubMed 38049866 ↗
  • Natuzzi M, Grange C, Grea T, Brichart T, Aigle A, Bechet D, Hautefeuille B, Thomas E, Ayoub JY, Bonnet JM, Louzier V, Allaouchiche B, Couturier A, Montembault A, de Oliveira PN, David L, Lux F, Tillement O. Feasibility study and direct extraction of endogenous free metallic cations combining hemodialysis and chelating polymer. Sci Rep. 2021 Oct 7;11(1):19948. doi: 10.1038/s41598-021-99462-y. PubMed 34620952 ↗
  • Couturier A, Serrand C, Masseguin C, Allaouchiche B, Tillement O, Lefrant JY, Barbar SD. Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (IRON-I.C.): protocol for a phase I-II randomised crossover pilot study. BMJ Open. 2025 Dec 23;15(12):e109783. doi: 10.1136/bmjopen-2025-109783. PubMed 41436269 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Nov 19, 2025
StartActual
Jun 4, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 2028
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07236463
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Jun 4, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Jun 5, 2026

Study contacts

Saber D BARBAR, MD, PhD
Contact
saber.barbar@chu-nimes.fr
0033466683320
Jean-Yves LEFRANT, MD, PhD
Contact
jean-yves.lefrant@chu-nimes.fr
0033466683320
Saber D BARBAR, MD, PhD
principal investigator · Centre Hospitalier Universitaire de Nīmes

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion